Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

psychedelic news

Don’t Miss

23 Oct 2023

News You Might Have Missed: Oct 23rd, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk
news

Don’t Miss

16 Oct 2023

News You Might Have Missed: Oct 16th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk
cybin deal

Finance

13 Oct 2023

Cybin Shareholders Approve Acquisition of Small Pharma

Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote....

By Microdose NewsDesk
psychedelic news

Don’t Miss

9 Oct 2023

News You Might Have Missed: Oct 9th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

california mushroom

Law & Politics

5 Oct 2023

California Passes Bill Allowing Doctors to Prescribe Psychedelics If Federally Re-Scheduled

California Governor Gavin Newsom has signed a bill that allows doctors to legally prescribe psychedelics when re-scheduled by the federal government....

By Microdose NewsDesk

Industry

4 Oct 2023

GH Research: Updates on Clinical Development Programs

5-MEO-DMT developer GH Research has provided an update on its main clinical programs....

By Microdose NewsDesk
news psychedelic

Don’t Miss

2 Oct 2023

News You Might Have Missed: Oct 2, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

28 Sep 2023

Numinus Announces $10 Million Equity Program

Numinus has announced an at-the-market equity offering program that allows the company to issue and sell up to $10,000,000 (CAD) of common shares....

By Microdose NewsDesk
FDA

Industry

27 Sep 2023

FDA Accepts PharmaTher’s New Drug Application for KETARX™ (Ketamine)

The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of April 29, 2024....

By Microdose NewsDesk

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.